Cargando…

Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology

INTRODUCTION: The impact of hepatorenal function on plasma biomarkers of neuropathology is unknown. Herein, we measured several plasma biomarkers in patients with cirrhosis. METHODS: Plasma phosphorylated tau (p‐tau181), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), total...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berry, Kacey, Asken, Breton M., Grab, Joshua D., Chan, Brandon, Lario Lago, Argentina, Wong, Randi, Seetharaman, Srilakshmi, LaHue, Sara C., Possin, Katherine L., Rojas, Julio C., Kramer, Joel H., Boxer, Adam L., Lai, Jennifer C., VandeVrede, Lawren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Fluid Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274803/ https://www.ncbi.nlm.nih.gov/pubmed/35845260 http://dx.doi.org/10.1002/dad2.12321

Ejemplares similares

Higher baseline levels of CSF inflammation increase risk of incident mild cognitive impairment and Alzheimer's disease dementia
por: Contreras, Joey A., et al.
Publicado: (2022)

Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume
por: Sapkota, Shraddha, et al.
Publicado: (2022)

Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction
por: Thanapornsangsuth, Poosanu, et al.
Publicado: (2022)

Deciphering the factors that influence participation in studies requiring serial lumbar punctures
por: Day, Gregory S., et al.
Publicado: (2020)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
por: Samudra, Niyatee, et al.
Publicado: (2023)

Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy
por: Lee, Young‐gun, et al.
Publicado: (2021)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
por: Bruno, Davide, et al.
Publicado: (2015)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease‐Opportunities for Therapy
por: Carare, Roxana O., et al.
Publicado: (2020)

Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD
por: Hajjar, Ihab, et al.
Publicado: (2020)

The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys
por: Boehnke, Susan E., et al.
Publicado: (2020)

An automated clinical mass spectrometric method for identification and quantification of variant and wild‐type amyloid‐β 1‐40 and 1‐42 peptides in CSF
por: DeMarco, Mari L., et al.
Publicado: (2020)

Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020)

A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease
por: Edwin, Trine Holt, et al.
Publicado: (2020)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
por: Hansson, Oskar, et al.
Publicado: (2020)

Association of cognitive impairment severity with potentially avoidable readmissions: A retrospective cohort study of 8897 older patients
por: Mitsutake, Seigo, et al.
Publicado: (2021)

Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity
por: Skillbäck, Tobias, et al.
Publicado: (2021)

Higher cerebrospinal fluid tau is associated with history of traumatic brain injury and reduced processing speed in Vietnam‐era veterans: A Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD‐ADNI) study
por: Clark, Alexandra L., et al.
Publicado: (2021)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Diagnostic and prognostic performance of CSF α‐synuclein in prion disease in the context of rapidly progressive dementia
por: Mastrangelo, Andrea, et al.
Publicado: (2021)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non‐converter Alzheimer's disease subjects with consideration for their amyloid beta status
por: Morar, Ulyana, et al.
Publicado: (2022)

Alzheimer’s pathology is associated with altered cognition, brain volume, and plasma biomarker patterns in traumatic encephalopathy syndrome
por: Asken, Breton M., et al.
Publicado: (2023)

NO/cGMP/pCREB re-activation reverses cognition deficits and attenuates amyloid-β neuropathology in transgenic models of Alzheimer’s disease
por: Thatcher, Gregory RJ, et al.
Publicado: (2013)

Intraventricular recombinant alpha-interferon in subacute sclerosing panencephalitis
por: Cianchetti, C., et al.
Publicado: (1991)

Effects of ventilation on the indoor spread of COVID-19
por: Bhagat, Rajesh K., et al.
Publicado: (2020)

Discovery of neuroprotective soluble guanylate cyclase modulators (GCMs) aciting via NO/GC/cGMP/CREB pathway
por: Siklos, Marton I, et al.
Publicado: (2013)

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2023)

CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
por: Horie, Kanta, et al.
Publicado: (2022)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

An NO Donor Approach to Neuroprotective and Procognitive Estrogen Therapy Overcomes Loss of NO Synthase Function and Potentially Thrombotic Risk
por: VandeVrede, Lawren, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1e6m98mluqp12ajt19f1qhq8kl